<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35438600</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>04</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>Nov</Month><Day>30</Day></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Research progress on vaccine efficacy against SARS-CoV-2 variants of concern.</ArticleTitle><Pagination><StartPage>2057161</StartPage><MedlinePgn>2057161</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2057161</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2022.2057161</ELocationID><Abstract><AbstractText>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to circulate worldwide and a variety of variants have emerged. Variants of concern (VOC) designated by the World Health Organization (WHO) have triggered epidemic waves due to their strong infectivity or pathogenicity and potential immune escape, among other reasons. Although large-scale vaccination campaigns undertaken globally have contributed to the improved control of SARS-CoV-2, the efficacies of current vaccines against VOCs have declined to various degrees. In particular, the highly infectious Delta and Omicron variants have caused recent epidemics and prompted concerns about control measures. This review summarizes current VOCs, the protective efficacy of vaccines against VOCs, and the shortcomings in methods for evaluating vaccine efficacy. In addition, strategies for responding to variants are proposed for future epidemic prevention and control as well as for vaccine research and development.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bian</LastName><ForeName>Lianlian</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Biological Products, Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jianyang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Biological Products, Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute of Biological Products, Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Qiushuang</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Institute of Biological Products, Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Institute of Biological Products, Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Qunying</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Institute of Biological Products, Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Xing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Institute of Biological Products, Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Miao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Biological Products, Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Zhenglun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Institute of Biological Products, Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000087507" MajorTopicYN="N">Vaccine Efficacy</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19 vaccine</Keyword><Keyword MajorTopicYN="N">Omicron</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">neutralizing antibodies</Keyword><Keyword MajorTopicYN="N">variant of concern</Keyword></KeywordList><CoiStatement>We declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work, there is no professional or other personal interest of any nature or kind in any product, service and/or company that could be construed as influencing the position presented in, or the review of, the manuscript entitled.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>19</Day><Hour>12</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35438600</ArticleId><ArticleId IdType="pmc">PMC9115786</ArticleId><ArticleId IdType="doi">10.1080/21645515.2022.2057161</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization(WHO) . COVID-19 vaccine tracker and landscape; 2022. 
[accessed 2022 Jan
18]. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.</Citation></Reference><Reference><Citation>World Health Organization(WHO) . Status of COVID-19 vaccines within WHO EUL/PQ evaluation process; 2021. 
[accessed 2021 Nov
11]. https://www.who.int/teams/regulation-prequalification/eul/covid-19.</Citation></Reference><Reference><Citation>World Health Organization(WHO) . WHO Coronavirus (COVID-19) Dashboard; 2022. 
[accessed 2022 Jan
18]. https://covid19.who.int/.</Citation></Reference><Reference><Citation>Canton R, De Lucas Ramos P, Garcia-Botella A, Garcia-Lledo A, Gomez-Pavon J, Gonzalez Del Castillo J, et al. New variants of SARS-CoV-2 Rev Esp Quimioter. 2021;34(5):419-428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8638835</ArticleId><ArticleId IdType="pubmed">34076402</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021;19:409–12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8167834</ArticleId><ArticleId IdType="pubmed">34075212</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med. 2021;385:585–94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8314739</ArticleId><ArticleId IdType="pubmed">34289274</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021;596:276–80.</Citation><ArticleIdList><ArticleId IdType="pubmed">34237773</ArticleId></ArticleIdList></Reference><Reference><Citation>Rössler A, Riepler L, Bante D, von Laer D, Kimpel J.. SARS-CoV-2 Omicron variant neutralization in serum from vaccinated and convalescent persons. N Engl J Med. 2022;386:698-700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8781314</ArticleId><ArticleId IdType="pubmed">35021005</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou D, Dejnirattisai W, Supasa P, Liu C, Mentzer AJ, Ginn HM, et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell. 2021;184:2348–61.e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7901269</ArticleId><ArticleId IdType="pubmed">33730597</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization(WHO) . Tracking SARS-CoV-2 variants; 2022. 
[accessed 2022 Jan 18]. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/.</Citation></Reference><Reference><Citation>World Health Organization(WHO) . COVID-19 Weekly Epidemiological Update; 2021. 
[accessed 2021 July 27]. https://www.who.int/docs/default-source/coronaviruse/20210722_weekly_epi_update_50_updated.pdf.</Citation></Reference><Reference><Citation>Bernal JL, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. N Engl J Med . 2024;385:585-594.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8314739</ArticleId><ArticleId IdType="pubmed">34289274</ArticleId></ArticleIdList></Reference><Reference><Citation>Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, et al. Efficacy of the ChAdox1 nCov-19 Covid-19 vaccine against the B.1.351 variant. N Engl J Med. 2021;384:1885–98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7993410</ArticleId><ArticleId IdType="pubmed">33725432</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Safety and efficacy of Single-Dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021;384:2187–201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8220996</ArticleId><ArticleId IdType="pubmed">33882225</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinde V, Bhikha S, Hoosain Z, Archary M, Bhorat Q, Fairlie L, et al. Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. N Engl J Med. 2021;384:1899–909.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8091623</ArticleId><ArticleId IdType="pubmed">33951374</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu-Raddad LJ, Chemaitelly H, Butt AA. Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants. N Engl J Med. 2021;385:187–89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8117967</ArticleId><ArticleId IdType="pubmed">33951357</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397:1819–29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8099315</ArticleId><ArticleId IdType="pubmed">33964222</ArticleId></ArticleIdList></Reference><Reference><Citation>CNCB  . Israel says Pfizer Covid vaccine is just 39% effective as delta spreads, but still prevents severe illness [accesed 23 July 2021]. https://www.cnbc.com/2021/07/23/delta-variant-pfizer-covid-vaccine-39percent-effective-in-israel-prevents-severe-illness.html.</Citation></Reference><Reference><Citation>Collie S, Champion J, Moultrie H, Bekker L-G, Gray G. Effectiveness of BNT162b2 vaccine against Omicron variant in South Africa. N Engl J Med . 2022;386:494–96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8757569</ArticleId><ArticleId IdType="pubmed">34965358</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581:215–20.</Citation><ArticleIdList><ArticleId IdType="pubmed">32225176</ArticleId></ArticleIdList></Reference><Reference><Citation>McCallum M, Marco A, Lempp F, Tortorici MA, Pinto D, Walls AC, et al. N-Terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell. 2021;184(9):2332-2347.e16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7962585</ArticleId><ArticleId IdType="pubmed">33761326</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerutti G, Guo Y, Zhou T, Gorman J, Lee M, Rapp M, et al. Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. Cell Host &amp; Microbe. 2021;29:819–33 e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7953435</ArticleId><ArticleId IdType="pubmed">33789084</ArticleId></ArticleIdList></Reference><Reference><Citation>Martínez-Flores D, Zepeda-Cervantes J, Cruz-Reséndiz A, Aguirre-Sampieri S, Sampieri A, Vaca L. SARS-CoV-2 vaccines based on the Spike Glycoprotein and implications of new viral variants. Front Immunol. 2021;12. doi:10.3389/fimmu.2021.701501.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.701501</ArticleId><ArticleId IdType="pmc">PMC8311925</ArticleId><ArticleId IdType="pubmed">34322129</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R, Zhang Q, Ge J, Ren W, Zhang R, Lan J, et al. Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species. Immunity. 2021;54:1611–21 e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8185182</ArticleId><ArticleId IdType="pubmed">34166623</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Boorla VS, Banerjee D, Chowdhury R, Cavener VS, Nissly RH, et al. Computational prediction of the effect of amino acid changes on the binding affinity between SARS-CoV-2 spike protein and the human ACE2 receptor. Proceedings of the National Academy of Sciences .2021;118:(42) e2106480118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8594574</ArticleId><ArticleId IdType="pubmed">34588290</ArticleId></ArticleIdList></Reference><Reference><Citation>Gan HH, Twaddle A, Marchand B, Gunsalus KC. Structural modeling of the SARS-CoV-2 Spike/Human ACE2 complex interface can identify high-affinity variants associated with increased transmissibility. J Mol Biol. 2021;433:167051.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8118711</ArticleId><ArticleId IdType="pubmed">33992693</ArticleId></ArticleIdList></Reference><Reference><Citation>Barton MI, MacGowan SA, Kutuzov MA, Dushek O, Barton GJ, van der Merwe PA. Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics. Elife. 2021;10:e70658.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8480977</ArticleId><ArticleId IdType="pubmed">34435953</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021;372:eabg3055.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8128288</ArticleId><ArticleId IdType="pubmed">33658326</ArticleId></ArticleIdList></Reference><Reference><Citation>Baum A, Fulton BO, Wloga E, Copin R, Pascal KE, Russo V, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020;369:1014–18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7299283</ArticleId><ArticleId IdType="pubmed">32540904</ArticleId></ArticleIdList></Reference><Reference><Citation>Diamond M, Chen R, Xie X, Case J, Zhang X, VanBlargan L, et al. SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies. Research Square. 2021;rs.3.rs-228079.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8058618</ArticleId><ArticleId IdType="pubmed">33664494</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021;593:130–35.</Citation><ArticleIdList><ArticleId IdType="pubmed">33684923</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi JCC , et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife. 2020;9:e61312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7723407</ArticleId><ArticleId IdType="pubmed">33112236</ArticleId></ArticleIdList></Reference><Reference><Citation>Collier DA, De Marco A, Ferreira I, Meng B, Datir RP, Walls AC, et al. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature. 2021;593:136–41.</Citation><ArticleIdList><ArticleId IdType="pubmed">33706364</ArticleId></ArticleIdList></Reference><Reference><Citation>Greaney AJ, Loes AN, Crawford KHD, Starr TN, Malone KD, Chu HY, et al. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host &amp; Microbe. 2021;29:463–76 e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7869748</ArticleId><ArticleId IdType="pubmed">33592168</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreano E, Piccini G, Licastro D, Casalino L, Johnson NV, Paciello I, et al. SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma doi: . bioRxiv. 2020.12.28.424451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8433494</ArticleId><ArticleId IdType="pubmed">34417349</ArticleId></ArticleIdList></Reference><Reference><Citation>McCallum M, Bassi J, De Marco A, Chen A, Walls AC, Di Iulio J, et al. SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern. Science. 2021;373(6555):648-654.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9835956</ArticleId><ArticleId IdType="pubmed">34210893</ArticleId></ArticleIdList></Reference><Reference><Citation>Mannar D, Saville JW, Zhu X, Srivastava SS, Berezuk AM, Tuttle KS, et al. SARS-CoV-2 Omicron variant: antibody evasion and cryo-EM structure of spike protein–ace2 complex. Science. 2022;375(6582):760-764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9799367</ArticleId><ArticleId IdType="pubmed">35050643</ArticleId></ArticleIdList></Reference><Reference><Citation>Teruel N, Crown M, Bashton M, Najmanovich R. Computational analysis of the effect of SARS-CoV-2 variant Omicron Spike protein mutations on dynamics, ACE2 binding and propensity for immune escape. bioRxiv; 2021. 10.1101/2021.12.14.472622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.12.14.472622</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratev F. The high transmission of SARS-CoV-2 Omicron (B.1.1.529) variant is not only due to its hACE2 binding: a free energy of perturbation study. bioRxiv; 2021. 10.1101/2021.12.04.471246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.12.04.471246</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan J, He X, Ren Y, Wang Z, Zhou H, Fan S, et al. Structural and computational insights into the SARS-CoV-2 Omicron RBD-ACE2 interaction. bioRxiv; 2022. 10.1101/2022.01.03.474855.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.01.03.474855</ArticleId><ArticleId IdType="pmc">PMC9007263</ArticleId><ArticleId IdType="pubmed">35418218</ArticleId></ArticleIdList></Reference><Reference><Citation>cov-lineages.org . PANGO. B.1.1.7; 2021. https://cov-lineages.org/global_report_B.1.1.7.html.</Citation></Reference><Reference><Citation>Rambaut, A, Nick Loman, N, Pybus, O, Barclay, W, Barrett, J, Carabelli, A, et al. Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations
2021. https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563.</Citation></Reference><Reference><Citation>Starr TN, Greaney AJ, Hilton SK, Ellis D, Crawford KHD, Dingens AS, et al. Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding. Cell. 2020;182:1295–310. e20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7418704</ArticleId><ArticleId IdType="pubmed">32841599</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemp SA, Collier DA, Datir RP, Ferreira I, Gayed S, Jahun A, et al. SARS-CoV-2 evolution during treatment of chronic infection. Nature. 2021;592:277–82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7610568</ArticleId><ArticleId IdType="pubmed">33545711</ArticleId></ArticleIdList></Reference><Reference><Citation>Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, et al. Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: insights from linking epidemiological and genetic data. medExiv 2020. 10.1101/2020.12.30.20249034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.12.30.20249034</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka H, Hirayama A, Nagai H, Shirai C, Takahashi Y, Shinomiya H, et al. Increased transmissibility of the SARS-CoV-2 Alpha variant in a Japanese population International journal of environmental research and public health. 2021;18(15): 7752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8345780</ArticleId><ArticleId IdType="pubmed">34360046</ArticleId></ArticleIdList></Reference><Reference><Citation>Barouch DH, Stephenson KE, Sadoff J, Yu J, Chang A, Gebre M, et al. Durable humoral and cellular immune responses 8 months after Ad26.COV2.S vaccination. N Engl J Med. 2021;385:951–53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8314733</ArticleId><ArticleId IdType="pubmed">34260834</ArticleId></ArticleIdList></Reference><Reference><Citation>A-Ry C, Yu J, McMahan K, Liu J, Chandrashekar A, Maron JS, et al. Differential kinetics of immune responses elicited by Covid-19 vaccines. N Engl J Med. 2021;385:2010–12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8531985</ArticleId><ArticleId IdType="pubmed">34648703</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen KW, Linderman SL, Moodie Z, Czartoski J, Lai L, Mantus G, et al. Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells. Cell Rep Med. 2021;2:100354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8253687</ArticleId><ArticleId IdType="pubmed">34250512</ArticleId></ArticleIdList></Reference><Reference><Citation>Azkur AK, Akdis M, Azkur D, Sokolowska M, van de Veen W, Brüggen M-C, et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy. 2020;75:1564–81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7272948</ArticleId><ArticleId IdType="pubmed">32396996</ArticleId></ArticleIdList></Reference><Reference><Citation>Novazzi F, Baj A, Genoni A, Spezia PG, Colombo A, Cassani G, et al. SARS-CoV-2 B.1.1.7 reinfection after previous COVID-19 in two immunocompetent Italian patients. J Med Virol. 2021;93:5648–49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8242781</ArticleId><ArticleId IdType="pubmed">33969504</ArticleId></ArticleIdList></Reference><Reference><Citation>Loconsole D, Sallustio A, Accogli M, Leaci A, Sanguedolce A, Parisi A, et al. Investigation of an outbreak of symptomatic SARS-CoV-2 VOC 202012/01-lineage B.1.1.7 infection in healthcare workers, Italy. Clin Microbiol Infect 2021;27(8):1174.e1-1174.e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8107058</ArticleId><ArticleId IdType="pubmed">33984489</ArticleId></ArticleIdList></Reference><Reference><Citation>Emary KRW, Golubchik T, Aley PK, Ariani CV, Angus B, Bibi S, et al. Efficacy of ChAdox1 nCov-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet. 2021;397:1351–62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8009612</ArticleId><ArticleId IdType="pubmed">33798499</ArticleId></ArticleIdList></Reference><Reference><Citation>Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N Engl J Med 2021. 385(13):1172-1183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8262625</ArticleId><ArticleId IdType="pubmed">34192426</ArticleId></ArticleIdList></Reference><Reference><Citation>cov-lineages.org . PANGO. B.1.351; 2021. https://cov-lineages.org/global_report_B.1.351.html.</Citation></Reference><Reference><Citation>Staub T, Arendt V, Lasso de la Vega EC, Braquet P, Michaux C, Kohnen M, et al. Case series of four re-infections with a SARS-CoV-2 B.1.351 variant, Luxembourg, February 2021. Euro Surv. 2021;26(18):2100423.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8103728</ArticleId><ArticleId IdType="pubmed">33960291</ArticleId></ArticleIdList></Reference><Reference><Citation>Saha S, Tanmoy AM, Hooda Y, Tanni AA, Goswami S, Sium SMA, et al. COVID-19 rise in Bangladesh correlates with increasing detection of B.1.351 variant. BMJ Global Health. 2021;6(5):e006012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8102859</ArticleId><ArticleId IdType="pubmed">33952579</ArticleId></ArticleIdList></Reference><Reference><Citation>Bian L, Gao F, Zhang J, He Q, Mao Q, Xu M, et al. Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies. Expert Rev Vaccines. 2021;20(4):365–73. doi:10.1080/14760584.2021.1903879.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2021.1903879</ArticleId><ArticleId IdType="pmc">PMC8054487</ArticleId><ArticleId IdType="pubmed">33851875</ArticleId></ArticleIdList></Reference><Reference><Citation>Novavax . Novavax COVID-19 vaccine demonstrates 89.3% efficacy in UK Phase 3 trial; 2021. 
[accessed 2021 Jan 28]. https://ir.novavax.com/2021-01-28-Novavax-COVID-19-Vaccine-Demonstrates-89-3-Efficacy-in-UK-Phase-3-Trial.</Citation></Reference><Reference><Citation>U.S. Food and Drug Administration (FDA) . Vaccines and related biological Products Advisory Committee February 26, 2021 meeting announcement; 2021[accessed February 26, 2021]. https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-february-26-2021-meeting-announcement.</Citation></Reference><Reference><Citation>Callaway E. Pfizer COVID vaccine protects against worrying coronavirus variants. Nature. 2021;593:325–26.</Citation><ArticleIdList><ArticleId IdType="pubmed">33963317</ArticleId></ArticleIdList></Reference><Reference><Citation>cov-lineages.org . PANGO. P.1; 2021. https://cov-lineages.org/global_report_P.1.html.</Citation></Reference><Reference><Citation>Faria NR, Mellan TA, Whittaker C, Claro IM, Candido DDS, Mishra S, et al. Genomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus, Brazil. medRxiv. 2021. doi:10.1101/2021.02.26.21252554.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.02.26.21252554</ArticleId><ArticleId IdType="pmc">PMC8139423</ArticleId><ArticleId IdType="pubmed">33853970</ArticleId></ArticleIdList></Reference><Reference><Citation>Faria NR, Mellan TA, Whittaker C, Claro IM, Candido DDS, Mishra S, et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science. 2021;372:815–21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8139423</ArticleId><ArticleId IdType="pubmed">33853970</ArticleId></ArticleIdList></Reference><Reference><Citation>Supasa P, Zhou D, Dejnirattisai W, Liu C, Mentzer AJ, Ginn HM, et al. Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. Cell. 2021;184:2201–11. e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7891044</ArticleId><ArticleId IdType="pubmed">33743891</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Chen Z, Azman AS, Sun R, Lu W, Zheng N, et al. Comprehensive mapping of neutralizing antibodies against SARS-CoV-2 variants induced by natural infection or vaccination. medRxiv 2021;2021.05.03.21256506. doi:10.1101/2021.05.03.21256506.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.05.03.21256506</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanriover MD, Doğanay HL, Akova M, Güner HR, Azap A, Akhan S, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;398:213–22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8266301</ArticleId><ArticleId IdType="pubmed">34246358</ArticleId></ArticleIdList></Reference><Reference><Citation>Álvarez-Antonio C, Meza-Sánchez G, Calampa C, Casanova W, Carey C, Alava F, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in Iquitos, Peru in July and August, 2020: a population-based study. Lancet Global Health. 2021;9:e925–e31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8133769</ArticleId><ArticleId IdType="pubmed">34022148</ArticleId></ArticleIdList></Reference><Reference><Citation>Peacock TP, Brown JC, Zhou J, Thakur N, Newman J, Kugathasan R, et al. The SARS-CoV-2 variant, Omicron, shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry. bioRxiv 2022; 2021.12.31.474653.</Citation></Reference><Reference><Citation>Callaway E. Delta coronavirus variant: scientists brace for impact. Nature. 2021;595:17–18.</Citation><ArticleIdList><ArticleId IdType="pubmed">34158664</ArticleId></ArticleIdList></Reference><Reference><Citation>Tchesnokova V, Kulasekara H, Larson L, Bowers V, Rechkina E, Kisiela D, et al. Acquisition of the L452R mutation in the ACE2-Binding interface of spike protein triggers recent massive expansion of SARS-CoV-2 variants. J Clin Microbiol. 2021;59:e0092121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8525575</ArticleId><ArticleId IdType="pubmed">34379531</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen H, Vusirikala, A, Flannagan, J, Twohig, KA, Zaidi, A, Chudasama, D. et al. Increased household transmission of COVID-19 cases associated with SARS-CoV-2 variant of concern B.1.617.2: a national case control study. The Lancet Regional Health- Europe. 2022;12:100252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8552812</ArticleId><ArticleId IdType="pubmed">34729548</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell F, Archer B, Laurenson-Schafer H, Jinnai Y, Konings F, Batra N, et al. Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021. Euro surveillance : bulletin Europeen sur les maladies transmissibles. European Communicable Disease Bulletin. ;2021;26(24):2100509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8212592</ArticleId><ArticleId IdType="pubmed">34142653</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang W, Shaman J. COVID-19 pandemic dynamics in India and impact of the SARS-CoV-2 Delta (B.1.617.2) variant. medExiv; 2021. 10.1101/2021.06.21.21259268.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.06.21.21259268</ArticleId><ArticleId IdType="pmc">PMC9169547</ArticleId><ArticleId IdType="pubmed">35670221</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma P, Mishra S, Basu S, Tanwar N, Kumar R. Breakthrough infection with SARS-CoV-2 and its predictors among healthcare workers in a medical college and hospital complex in Delhi, India. Cureus. 2021;13(10):e19070. doi:10.7759/cureus.19070.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.19070</ArticleId><ArticleId IdType="pmc">PMC8610433</ArticleId><ArticleId IdType="pubmed">34824945</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasreen S, Chung H, He S, Brown KA, Gubbay JB, Buchan SA, et al. Effectiveness of COVID-19 vaccines against variants of concern in Ontario, Canada. medRxiv; 2021. 10.1101/2021.06.28.21259420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.06.28.21259420</ArticleId></ArticleIdList></Reference><Reference><Citation>CNN. Why Covid-19 outbreaks in countries using Chinese vaccines don’t necessarily mean the shots have failed
[accessed July 03, 2021]
https://edition.cnn.com/2021/07/02/china/vaccines-sinovac-sinopharm-intl-hnk-dst/index.html.</Citation></Reference><Reference><Citation>Public Health England . Vaccines highly effective against hospitalisation from Delta variant; 2021. 
[Accessed 2021 June 14]. https://www.gov.uk/government/news/vaccines-highly-effective-against-hospitalisation-from-delta-variant.</Citation></Reference><Reference><Citation>World Health Organization(WHO) . Enhancing response to Omicron SARS-CoV-2 variant 2022 [accessed January 21, 2022]. https://www.who.int/publications/m/item/enhancing-readiness-for-omicron-(b.1.1.529)-technical-brief-and-priority-actions-for-member-states.</Citation></Reference><Reference><Citation>Qin S, Cui M, Sun S, Zhou J, Du Z, Cui Y, et al. Genome characterization and potential risk assessment of the novel SARS-CoV-2 variant Omicron (B.1.1.529). Zoonoses. 2021;1(1) doi:10.15212/ZOONOSES-2021-0024</Citation><ArticleIdList><ArticleId IdType="doi">10.15212/ZOONOSES-2021-0024</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y, Wang J, Jian F, Xiao T, Song W, Yisimayi A, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 2022;602(7898):657-663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8866119</ArticleId><ArticleId IdType="pubmed">35016194</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern. medRxiv; 2021. 10.1101/2021.12.14.21267615.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.12.14.21267615</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Espenhain L, Funk T, Overvad M, Edslev SM, Fonager J, Ingham AC, et al. Epidemiological characterisation of the first 785 SARS-CoV-2 Omicron variant cases in Denmark, December 2021. Euro Surveillance. 2021;26(50):2101146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8728489</ArticleId><ArticleId IdType="pubmed">34915977</ArticleId></ArticleIdList></Reference><Reference><Citation>UK Health Security Agency . SARS-CoV-2 variants of concern and variants under investigation in England Technical briefing 31; 2021. 
[accessed 2021 Dec 10]. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1042367/technical_briefing-31-10-december-2021.pdf.</Citation></Reference><Reference><Citation>Viana R, Moyo S, Amoako DG, Tegally H, Scheepers C, Althaus CL, et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature. 2022;603(7902):679-686.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8942855</ArticleId><ArticleId IdType="pubmed">35042229</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolter N, Jassat W, Walaza S, Welch R, Moultrie H, Groome M, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet. 2022;399(10323):437-446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8769664</ArticleId><ArticleId IdType="pubmed">35065011</ArticleId></ArticleIdList></Reference><Reference><Citation>UK Health Security Agency . SARS-CoV-2 variants of concern and variants under investigation in England technical briefing: update on hospitalisation and vaccine effectiveness for Omicron VOC-21NOV-01 (B.1.1.529); 2021. 
[accessed 2021 Dec 31]. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1045619/Technical-Briefing-31-Dec-2021-Omicron_severity_update.pdf.</Citation></Reference><Reference><Citation>Ulloa AC, Buchan SA, Daneman N, Brown KA. Early estimates of SARS-CoV-2 Omicron variant severity based on a matched cohort study. Ontario, Canada: medRxiv 2022:2021.12.24.21268382.</Citation></Reference><Reference><Citation>Lewnard JA, Hong PM VX, Kahn R, Lipsitch M, Tartof SY. Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in Southern California. medRxiv 2022. 10.1101/2022.01.11.22269045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.01.11.22269045</ArticleId><ArticleId IdType="pmc">PMC10208005</ArticleId><ArticleId IdType="pubmed">35675841</ArticleId></ArticleIdList></Reference><Reference><Citation>Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586:516–27.</Citation><ArticleIdList><ArticleId IdType="pubmed">32967006</ArticleId></ArticleIdList></Reference><Reference><Citation>Shuai H, Chan J-W, Hu B, Chai Y, Yuen T-T, Yin F, et al. Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron. Nature 2022;603(7902):693-699.</Citation><ArticleIdList><ArticleId IdType="pubmed">35062016</ArticleId></ArticleIdList></Reference><Reference><Citation>Halfmann PJ, Iida S, Iwatsuki-Horimoto K, Maemura T, Kiso M, Scheaffer SM, et al. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. Nature 2022;603(7902):687-692.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8942849</ArticleId><ArticleId IdType="pubmed">35062015</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng HF, Ackerson BK, Luo Y, Sy LS, Talarico CA, Tian Y, et al. Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants. Nat Med. 2022; 10.1038/s41591-022-01753-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01753-y</ArticleId><ArticleId IdType="pmc">PMC9117141</ArticleId><ArticleId IdType="pubmed">35189624</ArticleId></ArticleIdList></Reference><Reference><Citation>Stamatatos L, Czartoski J, Wan Y-H, Homad LJ, Rubin V, Glantz H, et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science. 2021;372:1413–18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8139425</ArticleId><ArticleId IdType="pubmed">33766944</ArticleId></ArticleIdList></Reference><Reference><Citation>Collier DA, De Marco A, Ferreira IATM, Meng B, Datir RP, Walls AC, et al. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature. 2021;593:136–41.</Citation><ArticleIdList><ArticleId IdType="pubmed">33706364</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. bioRxiv; 2021. doi:10.1101/2021.01.25.428137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.01.25.428137</ArticleId><ArticleId IdType="pubmed">33684923</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Beltran WF, Lam EC, St Denis K, Nitido AD, Garcia ZH, Hauser BM, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021;184:2523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8082941</ArticleId><ArticleId IdType="pubmed">33930298</ArticleId></ArticleIdList></Reference><Reference><Citation>Muik A, Wallisch A-K, Sänger B, Swanson KA, Mühl J, Chen W, et al. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera. Science. 2021;371:1152–53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7971771</ArticleId><ArticleId IdType="pubmed">33514629</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen X, Tang H, Pajon R, Smith G, Glenn GM, Shi W, et al. Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351. N Engl J Med. 2021;384:2352–54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8063884</ArticleId><ArticleId IdType="pubmed">33826819</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikegame S, Siddiquey MNA, Hung C-T, Haas G, Brambilla L, Oguntuyo KY, et al. Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants. Nat Commun. 2021;12:4598.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8313705</ArticleId><ArticleId IdType="pubmed">34312390</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuzmina A, Khalaila Y, Voloshin O, Keren-Naus A, Bohehm L, Raviv Y, et al. SARS CoV-2 escape variants exhibit differential infectivity and neutralization sensitivity to convalescent or post-vaccination sera. Available at SSRN: https://ssrn.com/abstract=3789258.2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7980135</ArticleId><ArticleId IdType="pubmed">33789085</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen X, Tang H, McDanal C, Wagh K, Fischer W, Theiler J, et al. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. Cell Host &amp; Microbe. 2021;29:529–39.e3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7934674</ArticleId><ArticleId IdType="pubmed">33705729</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, Arora P, Groß R, Seidel A, Hörnich BF, Hahn AS, et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell. 2021;184:2384–93.e12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7980144</ArticleId><ArticleId IdType="pubmed">33794143</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng X, Garcia-Knight MA, Khalid MM, Servellita V, Wang C, Morris MK, et al. Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation. medRxiv 2021. doi:10.1101/2021.03.07.21252647.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.07.21252647</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejnirattisai W, Zhou D, Supasa P, Liu C, Mentzer AJ, Ginn HM, et al. Antibody evasion by the P.1 strain of SARS-CoV-2. Cell. 2021;184:2939–54.e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8008340</ArticleId><ArticleId IdType="pubmed">33852911</ArticleId></ArticleIdList></Reference><Reference><Citation>Bates TA, Leier HC, Lyski ZL, McBride SK, Coulter FJ, Weinstein JB, et al. Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum. Nat Commun. 2021;12:5135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8390486</ArticleId><ArticleId IdType="pubmed">34446720</ArticleId></ArticleIdList></Reference><Reference><Citation>Vv E, Norwood C, Floyd K, Lai L, Me D-G, Wh H, et al. Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. Cell Host Microbe. 2021;29:516–21.e3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7980225</ArticleId><ArticleId IdType="pubmed">33798491</ArticleId></ArticleIdList></Reference><Reference><Citation>Tada T, Dcosta BM, Samanovic MI, Herati RS, Cornelius A, Zhou H, et al. Convalescent-Phase sera and vaccine-elicited antibodies largely maintain neutralizing titer against global SARS-CoV-2 variant spikes. mBio. 2021;12:e00696-21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8262901</ArticleId><ArticleId IdType="pubmed">34060334</ArticleId></ArticleIdList></Reference><Reference><Citation>Vv E, Wh H, Xie X, Ahmed R, Ms S. Neutralizing antibodies against SARS-CoV-2 variants after infection and vaccination. Jama. 2021;325:1896–98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7980146</ArticleId><ArticleId IdType="pubmed">33739374</ArticleId></ArticleIdList></Reference><Reference><Citation>Lustig Y, Nemet I, Kliker L, Zuckerman N, Yishai R, Alroy-Preis S, et al. Neutralizing response against variants after SARS-CoV-2 infection and One Dose of BNT162b2. N Engl J Med. 2021;384:2453–54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8063887</ArticleId><ArticleId IdType="pubmed">33826815</ArticleId></ArticleIdList></Reference><Reference><Citation>Vv E, Norwood C, Floyd K, Lai L, Me D-G, Wh H, et al. Reduced binding and neutralization of infection- and vaccine-induced antibodies to the B.1.351 (South African) SARS-CoV-2 variant. bioRxiv. 2021;2021.02.20.432046.</Citation></Reference><Reference><Citation>Chen RE, Zhang X, Case JB, Winkler ES, Liu Y, VanBlargan LA, et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat Med. 2021;27:717–26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8058618</ArticleId><ArticleId IdType="pubmed">33664494</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D, Bruel T, Grzelak L, Guivel-Benhassine F, Staropoli I, Porrot F, et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat Med. 2021;27:917–24.</Citation><ArticleIdList><ArticleId IdType="pubmed">33772244</ArticleId></ArticleIdList></Reference><Reference><Citation>Betton M, Livrozet M, Planas D, Fayol A, Monel B, Védie B, et al. Sera neutralizing activities against severe acute respiratory syndrome Coronavirus 2 and multiple variants 6 Months after hospitalization for Coronavirus disease 2019. Clin Infect Dis. 2021;73:e1337–e44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8083257</ArticleId><ArticleId IdType="pubmed">33851216</ArticleId></ArticleIdList></Reference><Reference><Citation>Wall EC, Wu M, Harvey R, Kelly G, Warchal S, Sawyer C, et al. AZD1222-Induced neutralising antibody activity against SARS-CoV-2 Delta VOC. Lancet. 2021;398:207–09.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8238446</ArticleId><ArticleId IdType="pubmed">34197809</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Liu Y, Xia H, Zou J, Weaver SC, Swanson KA, et al. Bnt162b2-Elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature. 2021;596:273–75.</Citation><ArticleIdList><ArticleId IdType="pubmed">34111888</ArticleId></ArticleIdList></Reference><Reference><Citation>Wall EC, Wu M, Harvey R, Kelly G, Warchal S, Sawyer C, et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet. 2021;397:2331–33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8175044</ArticleId><ArticleId IdType="pubmed">34090624</ArticleId></ArticleIdList></Reference><Reference><Citation>Sapkal GN, Yadav PD, Sahay RR, Deshpande G, Gupta N, Nyayanit DA, et al. Neutralization of Delta variant with sera of Covishield™ vaccines and COVID-19-recovered vaccinated individuals. J Travel Med. 2021;28(7):taab119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8385819</ArticleId><ArticleId IdType="pubmed">34343316</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav PD, Sapkal GN, Ella R, Sahay RR, Nyayanit DA, Patil DY, et al. Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin. J Travel Med. 2021;28(7):taab104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8344909</ArticleId><ArticleId IdType="pubmed">34230972</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C, Ginn HM, Dejnirattisai W, Supasa P, Wang B, Tuekprakhon A, et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell. 2021;184:4220–36.e13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8218332</ArticleId><ArticleId IdType="pubmed">34242578</ArticleId></ArticleIdList></Reference><Reference><Citation>Haveri A, Ekström N, Solastie A, Virta C, Österlund P, Isosaari E, et al. Persistence of neutralizing antibodies a year after SARS-CoV-2 infection in humans. Eur J Immunol. 2021;51:3202–13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8646652</ArticleId><ArticleId IdType="pubmed">34580856</ArticleId></ArticleIdList></Reference><Reference><Citation>Carreño JM, Alshammary H, Singh G, Raskin A, Amanat F, Amoako A, et al. Reduced neutralizing activity of post-SARS-CoV-2 vaccination serum against variants B.1.617.2, B.1.351, B.1.1.7+E484K and a sub-variant of C.37. medRxiv; 2021. 10.1101/2021.07.21.21260961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.07.21.21260961</ArticleId></ArticleIdList></Reference><Reference><Citation>Mlcochova P, Kemp SA, Dhar MS, Papa G, Meng B, Ferreira IATM, et al. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature. 2021;599:114–19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8566220</ArticleId><ArticleId IdType="pubmed">34488225</ArticleId></ArticleIdList></Reference><Reference><Citation>Vacharathit V, Aiewsakun P, Manopwisedjaroen S, Srisaowakarn C, Laopanupong T, Ludowyke N, et al. CoronaVac induces lower neutralising activity against variants of concern than natural infection. Lancet Infect Dis. 2021;21:1352–54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8389976</ArticleId><ArticleId IdType="pubmed">34454652</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis C, Logan N, Tyson G, Orton R, Harvey WT, Perkins JS, et al. Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination. PLoS Pathog. 2021;17:e1010022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8639073</ArticleId><ArticleId IdType="pubmed">34855916</ArticleId></ArticleIdList></Reference><Reference><Citation>Jongeneelen M, Kaszas K, Veldman D, Huizingh J, Rvd V, Schouten T, et al. Ad26.Cov2. S elicited neutralizing activity against Delta and other SARS-CoV-2 variants of concern bioRxiv; 2021. 10.1101/2021.07.01.450707.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.07.01.450707</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi A, Koch M, Wu K, Dixon G, Oestreicher J, Legault H, et al. Serum neutralizing activity of mRNA-1273 against SARS-CoV-2 variants. J Virol. 2021;95:e01313–21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8577347</ArticleId><ArticleId IdType="pubmed">34549975</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J, X-Y W, Xiang J, Peng P, F-L X, Wu K, et al. Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera. Genes &amp; Diseases;2021. doi:10.1016/j.gendis.2021.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gendis.2021.11.007</ArticleId><ArticleId IdType="pmc">PMC8639289</ArticleId><ArticleId IdType="pubmed">34877393</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X, Zheng A, Li D, Zhang R, Sun H, Wang Q, et al. Neutralisation of ZF2001-elicited antisera to SARS-CoV-2 variants. Lancet Microbe. 2021;2(10):e494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8378832</ArticleId><ArticleId IdType="pubmed">34458880</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, Hofmann-Winkler H, Krüger N, Kempf A, Nehlmeier I, Graichen L, et al. SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination. Cell Rep. 2021;36(3):109415.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8238662</ArticleId><ArticleId IdType="pubmed">34270919</ArticleId></ArticleIdList></Reference><Reference><Citation>Tada T, Zhou H, Dcosta BM, Samanovic MI, Mulligan MJ, Landau NR. Partial resistance of SARS-CoV-2 Delta variants to vaccine-elicited antibodies and convalescent sera. iScience. 2021;24(11):103341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8541826</ArticleId><ArticleId IdType="pubmed">34723159</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen CH, Schelde AB, Moustsen-Helm IR, Emborg H-D, Krause TG, Mølbak K, et al. Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: a Danish cohort study. medRxiv 2021. 10.1101/2021.12.20.21267966.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.12.20.21267966</ArticleId></ArticleIdList></Reference><Reference><Citation>Altarawneh H, Chemaitelly H, Tang P, Hasan MR, Qassim S, Ayoub HH, et al. Protection afforded by prior infection against SARS-CoV-2 reinfection with the Omicron variant. medRxiv 2022; 2022.01.05.22268782. 10.1101/2022.01.05.22268782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.01.05.22268782</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson &amp; Johnson. Johnson &amp; Johnson COVID-19 vaccine authorized by U.S. FDA for emergency use - first single-shot vaccine in fight against global pandemic
https://www.jnj.com/johnson-johnson-covid-19-vaccine-authorized-by-u-s-fda-for-emergency-usefirst-single-shot-vaccine-in-fight-against-global-pandemic.</Citation></Reference><Reference><Citation>Oxford . Oxford Covid-19 vaccine trial results; 2021. 
[accessed 2021 Feb 7]. https://www.wits.ac.za/covid19/covid19-news/latest/oxford-covid-19-vaccine-trial-results.html.</Citation></Reference><Reference><Citation>Voysey M, Ann Costa Clemens S, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Single-Dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdox1 nCov-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397:881–91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7894131</ArticleId><ArticleId IdType="pubmed">33617777</ArticleId></ArticleIdList></Reference><Reference><Citation>Callaway E, Mallapaty S. Novavax offers first evidence that COVID vaccines protect people against variants. Nature. 2021;590:17.</Citation><ArticleIdList><ArticleId IdType="pubmed">33510489</ArticleId></ArticleIdList></Reference><Reference><Citation>Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N Engl J Med. 2021;385:1172–83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8262625</ArticleId><ArticleId IdType="pubmed">34192426</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet. 2021;397:1725–35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8064668</ArticleId><ArticleId IdType="pubmed">33901423</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan L, Yu Y, Wu X, Nie J, Zhang J, Wang Z, et al. The first Chinese national standards for SARS-CoV-2 neutralizing antibody. Vaccine. 2021;39:3724–30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8133612</ArticleId><ArticleId IdType="pubmed">34059373</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Beltran WF, Lam EC, St Denis K, Nitido AD, Garcia ZH, Hauser BM, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021;184:2372–83 e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7953441</ArticleId><ArticleId IdType="pubmed">33743213</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Biological Standards and Control (NIBSC) . First WHO international standard anti-SARS-CoV-2 immunoglobulin (Human); 2021. https://www.nibsc.org/documents/ifu/20-136.pdf.</Citation></Reference><Reference><Citation>Huang B, Dai L, Wang H, Hu Z, Yang X, Tan W, et al. Serum sample neutralisation of BBIBP-CorV and ZF2001 vaccines to SARS-CoV-2 501Y.V2. Lancet Microbe. 2021;2:e285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8043583</ArticleId><ArticleId IdType="pubmed">33870240</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathan A, Rossin EJ, Kaseke C, Park RJ, Khatri A, Koundakjian D, et al. Structure-Guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses. Cell. 2021;184(17):4401-4413.e10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8241654</ArticleId><ArticleId IdType="pubmed">34265281</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer RJ, van Doremalen N, Adney DR, Yinda CK, Port JR, Holbrook MG, et al. ChAdox1 nCov-19 (AZD1222) protects hamsters against SARS-CoV-2 B.1.351 and B.1.1.7 disease. Nat Commun. 2021;12(1):5868.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8497486</ArticleId><ArticleId IdType="pubmed">34620866</ArticleId></ArticleIdList></Reference><Reference><Citation>Alter G, Yu J, Liu J, Chandrashekar A, Borducchi EN, Tostanoski LH, et al. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans. Nature. 2021;596(7871):268-272.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8357629</ArticleId><ArticleId IdType="pubmed">34107529</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Food and Drug Administration (FDA) . Joint CDC and FDA statement on vaccine boosters; 2021. 
[accessed 2021 July 08]. https://www.fda.gov/news-events/press-announcements/joint-cdc-and-fda-statement-vaccine-boosters.</Citation></Reference><Reference><Citation>Ministry of Health. The Vaccination Advisory Committee Presented Data and Recommended the Administration of a Third Dose to Older Adults; 2021. https://www.gov.il/en/departments/news/29072021-04</Citation></Reference><Reference><Citation>He Q, Mao Q, An C, Zhang J, Gao F, Bian L, et al. Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates. Emerging Microbes &amp; Infections. 2021;10:629–37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8009122</ArticleId><ArticleId IdType="pubmed">33691606</ArticleId></ArticleIdList></Reference><Reference><Citation>Groß R, Zanoni M, Seidel A, Conzelmann C, Gilg A, Krnavek D, et al. Heterologous ChAdox1 nCov-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity. EBioMedicine. 2022;75:103761.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8682749</ArticleId><ArticleId IdType="pubmed">34929493</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Shaw RH, Stuart ASV, Greenland M, Dinesh T, Provstgaard-Morys S, et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet. 2021;398(10303):856-869.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8346248</ArticleId><ArticleId IdType="pubmed">34370971</ArticleId></ArticleIdList></Reference><Reference><Citation>Oxford . Preliminary data suggests mixing Covid-19 vaccine increases reactogenicity; 2021. [accessed 2021 May 13].
https://www.ox.ac.uk/news/2021-05-13-preliminary-data-suggests-mixing-covid-19-vaccine-increases-reactogenicity.</Citation></Reference><Reference><Citation>U.S. Food and Drug Administration (FDA) . Emergency use authorization for vaccines to prevent COVID-19-guidance for industry; 2021
[accessed 2021 May 25]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/emergency-use-authorization-vaccines-prevent-covid-19.</Citation></Reference><Reference><Citation>Medicines &amp; Healthcare products Regulatory Agency . Guidance on strain changes in authorised COVID-19 vaccines; 2021. [accessed 2021 March 04]. https://www.gov.uk/government/publications/access-consortium-guidance-on-strain-changes-in-authorised-covid-19-vaccines/guidance-on-strain-changes-in-authorised-covid-19-vaccines.</Citation></Reference><Reference><Citation>European Medicines Agency (EMA) . Reflection paper on the regulatory requirements for vaccines intended to provide protection against variant strain(s) of SARS-CoV-2; 2021
[accessed 2021 Feb 25]. https://www.ema.europa.eu/en/regulatory-requirements-vaccines-intended-provide-protection-against-variant-strains-sars-cov-2.</Citation></Reference><Reference><Citation>World Health Organization(WHO) . Considerations for evaluation of modified COVID-19 vaccines. In: (RPQ) RaP, ed; 2021.  [Accessed 2021 Mar 12]. https://extranet.who.int/pqweb/sites/default/files/documents/Addendum_Evaluation_Modified_Covid-19%20Vaccine.pdf</Citation></Reference><Reference><Citation>Omicron COVID same old, scariant or game changer?
2021. https://member.procurementleaders.com/wp-content/uploads/The%20State%20of%20the%20Pandemic%20-%20with%20Juan%20Enriquez.pdf.</Citation></Reference><Reference><Citation>Johnson &amp; Johnson . Johnson &amp; Johnson to evaluate its COVID-19 vaccine against New Omicron COVID-19 variant; 2021. 
[accessed 2021 Nov 29]. https://www.jnj.com/johnson-johnson-to-evaluate-its-covid-19-vaccine-against-new-omicron-covid-19-variant.</Citation></Reference><Reference><Citation>Novavax . Novavax statement on Omicron variant response; 2021. [accessed 2021 Dec 02]. https://ir.novavax.com/Novavax-Statement-on-Omicron-Variant-Response</Citation></Reference><Reference><Citation>Pfizer . Pfizer and BioNtech Provide Update on Omicron Variant; 2021. [accessed 2021 Dec 08]. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-provide-update-omicron-variant.</Citation></Reference><Reference><Citation>AstraZeneca , Oxford Announce Work on New Version of COVID-19 Vaccine Against Omicron; 2021
[accessed 2021 Dec
22]. https://www.republicworld.com/world-news/uk-news/astrazeneca-oxford-announce-work-on-new-version-of-covid-19-vaccine-against-omicron.html.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>